SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab
BASEL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group,announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.
“The initiation of this Phase 2 study is an important step in the clinical development of nanrilkefusp alfa. In addition to our previous and ongoing studies to determine the efficacy of nanrilkefusp alfa in combination with checkpoint blockers, we now aim to determine its ability to enhance the antibody dependent cellular cytotoxicity exerted by cetuximab,” said Richard Sachse, M.D., Ph.D., chief medical officer of SOTIO. “If replicated in patients, the increased anti-tumor activity and proliferation of CD8+ T-cells that has been observed in colorectal cancer models treated with IL-15 superagonists could position nanrilkefusp alfa as a safe and effective therapy in combination with cetuximab in this indication. We look forward to evaluating this potential benefit.”
The Phase 2 AURELIO-05 trial (NCT05619172) is an open-label, single-arm, multicenter study to evaluate the efficacy and safety of nanrilkefusp alfa in combination with cetuximab in up to 52 patients with RAS wild-type colorectal cancer who are relapsed/refractory or intolerant to prior treatment with irinotecan- and oxaliplatin-containing chemotherapy. The trial will be conducted in approximately 20 specialized sites across Europe. The first patient was dosed at the Gent University Hospital (Belgium), under the supervision of Professor Karen Geboes, head of the Department of Gastrointestinal and Intestinal Diseases.
Professor Eric van Cutsem, head of Digestive Oncology at the University Hospital in Leuven (Belgium) and coordinating investigator of the AURELIO-05 trial commented: “Despite recent advances in oncology, patients with advanced refractory colorectal cancer still have poor long term survival rates. Having already demonstrated promising signs of safety and efficacy not only in monotherapy, but also in combination with another approved monoclonal antibody, pembrolizumab, we are pleased to have initiated this critical study to evaluate the potential benefit of nanrilkefusp alfa in combination with cetuximab in this highly underserved patient population.”
About nanrilkefusp alfa and IL-15 Superagonist Technology:
Nanrilkefusp alfa (previously known as SOT101) is the lead candidate from SOTIO’s IL-15 technology platform. Nanrilkefusp alfa is a subcutaneously administered IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. Nanrilkefusp alfa has demonstrated strong preclinical in vivo efficacy in various tumor models showing increased long-term survival and tumor regression, as well as a favorable toxicology profile. Nanrilkefusp alfa has been shown in preclinical models to synergize with checkpoint inhibitors and antibody therapies exerting antibody dependent cellular cytotoxicity (ADCC).
Along with Interleukin-2 (IL-2), IL-15 activity is known to increase the number of cytotoxic T cells and NK cells, the two most important cells for driving an anti-cancer immune response. This T and NK cell expansion is the result of IL-15 binding to its IL-15 alpha chain receptor in conjunction with binding to its shared IL-2/IL-15 beta gamma receptor on the surface of T and NK cells. Nanrilkefusp alfa has been precisely designed and optimized for its use as a potent immunotherapy by addressing two important design issues that limit current IL-2 and IL-15 approaches. These include selectively binding only to cytotoxic T and NK cells, while avoiding other cell types associated with adverse events, and stimulating T and NK cells through pulses in cytokine concentrations rather than tonic stimulation.
|Company contact:||Media contact:|
|Richard Kapsa||Michael Tattory|
|Head of Communication||LifeSci Communications|
|T:(+420) 224 174 448||T:(+1) 609-802-6265|
|M:(+420) 603 280 firstname.lastname@example.org|
About SOTIO Biotech
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The robust SOTIO clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, nanrilkefusp alfa, currently being tested in phase II clinical trials, SOT102, a next generation Claudin-18.2-targeted antibody-drug conjugate (ADC) which entered the clinical phase in 2022, and SOT106, a novel ADC which is currently in preclinical studies. BOXR1030, a GPC3-targeted CAR-T based on proprietary technology designed to improve on the efficacy of CAR-T therapies in the tumor microenvironment, is entering the clinical phase. SOTIO is a member of the PPF Group. For more information, please visit the company’s website at www.sotio.com.
SOTIO is a registered trademark of SOTIO Biotech a.s. in selected countries.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Årsrapport for 2022 - Selskabsmeddelelse nr. 1/202327.3.2023 23:07:48 CEST | pressemeddelelse
ÅRSRAPPORT FOR 2022 UDBYTTESTRØM OG LIKVIDITET BEDRE END FORVENTET, TIL TRODS FOR SVÆRE MARKEDER PÅVIRKET AF COVID Hovedpunkter for 2022 - Koncernen Resultat for året blev et tab på DKK 1,5 mio. (DKK -0,5 mio.).Totale pengestrømme for året på DKK -9,1 mio. (2021: positive pengestrømme på DKK 0,8 mio.)Likvide midler pr. 31. december 2022 på DKK 13,0 (DKK 21,9 mio.), heraf DKK 3,5 mio. i moderselskabet EAC Invest, DKK 5,8 mio. i Thailand og DKK 3,7 mio. indestår i Kina og er ikke til umiddelbar disposition for EAC Invest koncernen udenfor Kina.Udbytter fra investeringer udgjorde DKK 3,4 mio., og var lidt højere end oprindeligt forventet.Thai Poly Acrylic var i 2022 hårdt ramt af efterdønninger fra Covid-19 og stigende priser på råmaterialer, hvilket påvirkede salget og resultatet var betydeligt under forventning.Udbyttebetaling på DKK 1.000 pr. aktie og i alt DKK 10 mio. blev gennemført i april 2022. Forventninger for 2023 - Koncernen Forventede driftsomkostninger (primært driftsresultat
Nyxoah Raises $3 Million from an At-the-Market Equity Offering27.3.2023 22:05:00 CEST | Press release
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $3 Million from an At-the-Market Equity Offering Mont-Saint-Guibert, Belgium – March 27, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $2.8 million in gross proceeds pursuant to the Company’s $50 million at-the-market ("ATM") program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The shares were purchased by historical Nyxoah shareholder Cochlear Limited, and the proceeds will be used for general corporate purposes. The ordinary shares described above were sold pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-268955), previously filed with the Securities and Exchange Commission (“SEC
Convocation of the 2023 Annual General Meeting of Shareholders and Proposed Resolutions27.3.2023 20:30:00 CEST | Press release
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014). EINDHOVEN, Pays-Bas et LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, March 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the Company), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today has convened the 2023 Annual General Meeting of Shareholders (AGM), including the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on May 8, 2023. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2022, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2022 statutory accounts were filed with the Netherlands Authority for the Fina
ONWARD Reports 2022 Full Year Financial and Operating Results27.3.2023 20:00:00 CEST | Press release
Company also Provides Business Update and Outlook for 2023 - Conference Call and Webcast (in English) March 28, 2023, at 2:00 PM CEST/8:00 AM EDT THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, LAUSANNE, Switzerland & BOSTON, MA USA, March 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces its 2022 financial and operating results. The full Annual Report is available here, on the Company’s website in the Investors section (https://ir.onwd.com), and on the website of the Netherlands Authority for the Financial Markets (www.afm.nl). “I am proud of the volume and significance of our team’s achievements as we prepare for commercialization of our first therapy in late 2023 or early 2024,” said Dave Marver, CEO
Nokia Corporation: Repurchase of own shares on 27.03.202327.3.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 27 March 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 27.03.2023 Espoo, Finland – On 27 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL284,4184.39CEUX14,3074.40AQEU2904.39TQEX9854.38Total300,0004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and en